Patients with MODY1 have characteristic changes in the insulin secretory response to glucose, i.e., these patients are characterized by beta cell dysfunction, which differs from the clinical picture of MODY patients with glucokinase gene damage (MODY2) (Figure 2). This evidence concerns the gene GCK and maturity-onset diabetes of the young type 2.